MeranzinCAS# 23971-42-8 |
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 23971-42-8 | SDF | Download SDF |
| PubChem ID | 1803558 | Appearance | Cryst. |
| Formula | C15H16O4 | M.Wt | 260.3 |
| Type of Compound | Coumarins | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | 8-[[(2S)-3,3-dimethyloxiran-2-yl]methyl]-7-methoxychromen-2-one | ||
| SMILES | CC1(C(O1)CC2=C(C=CC3=C2OC(=O)C=C3)OC)C | ||
| Standard InChIKey | LSZONYLDFHGRDP-LBPRGKRZSA-N | ||
| Standard InChI | InChI=1S/C15H16O4/c1-15(2)12(19-15)8-10-11(17-3)6-4-9-5-7-13(16)18-14(9)10/h4-7,12H,8H2,1-3H3/t12-/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | 1. Meranzin hydrate can induce similar effect to Fructus Aurantii on intestinal motility and it was, at least in part, mediated by stimulation of H1 histamine receptors. 2. Meranzin exhibits strong anti-inflammatory and analgesic activity. |
| Targets | Immunology & Inflammation related |
Meranzin Dilution Calculator
Meranzin Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 3.8417 mL | 19.2086 mL | 38.4172 mL | 76.8344 mL | 96.043 mL |
| 5 mM | 0.7683 mL | 3.8417 mL | 7.6834 mL | 15.3669 mL | 19.2086 mL |
| 10 mM | 0.3842 mL | 1.9209 mL | 3.8417 mL | 7.6834 mL | 9.6043 mL |
| 50 mM | 0.0768 mL | 0.3842 mL | 0.7683 mL | 1.5367 mL | 1.9209 mL |
| 100 mM | 0.0384 mL | 0.1921 mL | 0.3842 mL | 0.7683 mL | 0.9604 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- 4,4'-Bis(5-methyl-2-benzoxazolyl)stilbene
Catalog No.:BCC8657
CAS No.:2397-00-4
- Glochidonol
Catalog No.:BCN5091
CAS No.:23963-54-4
- 5-[(2R)-2-Aminopropyl]-1-[3-(benzoyloxy)propyl]-2,3-dihydro-1H-indole-7-carbonitrile (2R,3R)-2,3-dihydroxybutanedioate
Catalog No.:BCN1479
CAS No.:239463-85-5
- 5-(2-Aminopropyl)-7-cyanoindolin-1-yl)propyl benzoate
Catalog No.:BCC8718
CAS No.:239463-72-0
- Alphaxalone
Catalog No.:BCC7545
CAS No.:23930-19-0
- Dexamethasone dipropionate
Catalog No.:BCC8934
CAS No.:55541-30-5
- Z-Lys(Boc)-OH
Catalog No.:BCC2763
CAS No.:2389-60-8
- H-Lys(Boc)-OMe.HCl
Catalog No.:BCC2983
CAS No.:2389-48-2
- Boc-Lys(Z)-OH
Catalog No.:BCC2722
CAS No.:2389-45-9
- Zapotinin
Catalog No.:BCC9192
CAS No.:14813-20-8
- Tosedostat (CHR2797)
Catalog No.:BCC2309
CAS No.:238750-77-1
- Ethyl2-bromo-4H-thieno[3,2-b]pyrrole-5-carboxylate
Catalog No.:BCC8979
CAS No.:238749-50-3
- Delta-9-Tetrahydrocannabinolic acid
Catalog No.:BCN8098
CAS No.:23978-85-0
- Tolnaftate
Catalog No.:BCC4869
CAS No.:2398-96-1
- 13-Deacetyltaxachitriene A
Catalog No.:BCN7390
CAS No.:239800-99-8
- Dehydroepiandrosterone enanthate
Catalog No.:BCC8930
CAS No.:23983-43-9
- Pyrocatechol monoglucoside
Catalog No.:BCN4667
CAS No.:2400-71-7
- QX 314 bromide
Catalog No.:BCC6889
CAS No.:24003-58-5
- Griffithazanone A
Catalog No.:BCN4813
CAS No.:240122-30-9
- Griffithinam
Catalog No.:BCN4744
CAS No.:240122-32-1
- 2-Amino-3-benzyloxypyridine
Catalog No.:BCC8524
CAS No.:24016-03-3
- Agathadiol diacetate
Catalog No.:BCN5093
CAS No.:24022-13-7
- H-Glu-pNA
Catalog No.:BCC2923
CAS No.:24032-35-7
- Salvicine
Catalog No.:BCN3163
CAS No.:240423-23-8
Pharmacokinetic study of the prokinetic compounds meranzin hydrate and ferulic acid following oral administration of Chaihu-Shugan-San to patients with functional dyspepsia.[Pubmed:21605652]
J Ethnopharmacol. 2011 Sep 1;137(1):205-13.
AIM OF THE STUDY: The prokinetic activity of ferulic acid derived from Ligusticum chuanxiong hort in the Chaihu-Shugan-San formula has been shown to be similar to Chaihu-Shugan-San, a popular traditional Chinese medicine for treating functional dyspepsia. The effects of Meranzin hydrate, a compound isolated from Fructus aurantii in the Chaihu-Shugan-San formula, are unclear, as the pharmacokinetics have never been studied in patients with functional dyspepsia. This study aimed to describe the pharmacokinetics of ferulic acid and merazin hydrate by evaluating the prokinetics induced by Chaihu-Shugan-San and Meranzin hydrate. MATERIALS AND METHODS: Gastric emptying and intestinal transit were measured after oral administration of a single dose of Chaihu-Shugan-San or Meranzin hydrate in rats. The tone of rat ileum was selected as direct evidence of the prokinetic activity of Meranzin hydrate. Patients with functional dyspepsia were recruited, and Meranzin hydrate and ferulic acid were identified by ultra performance liquid chromatography with tandem mass spectrometry in the plasma of patients following a single oral administration of Chaihu-Shugan-San. The resulting pharmacokinetic properties were determined by ultra performance liquid chromatography coupled to photo diode array. RESULTS: In rats, single doses of Chaihu-Shugan-San (20 g/kg) and Meranzin hydrate (28 mg/kg) significantly accelerated gastric emptying and intestinal transit (Chaihu-Shugan-San: 68.9 +/- 5.6% and 72.3 +/- 4.7%, Meranzin hydrate: 72.9 +/- 3.8% and 75.2 +/- 3.1%) compared with the control (55.45 +/- 3.7% and 63.51 +/- 5.1%, P<0.05), showing similar results as cisapride (69.6 +/- 4.8% and 71.6 +/- 6.3%). Meranzin hydrate (30, 100 mumol/L) directly increased the amplitude of rat ileum compared with the control (P<0.01). The pharmacokinetics profiles of Meranzin hydrate and ferulic acid in patient plasma was fitted with a two-compartment model detected by a simple, rapid and accurate UPLC method. Time to reach peak concentration of Meranzin hydrate (0.371 mg/L) and ferulic acid (0.199 mg/L) was 23.57 min and 27.50 min, respectively. The elimination half-life and area under the concentration-time curve from t=0 to the last time of Meranzin hydrate and ferulic acid were 139.53 min and 31.445 mug min/mL and 131.27 min and 14.835 mug min/mL, respectively. The absorption constant and volume of distribution of Meranzin hydrate and ferulic acid were 0.185 +/- 0.065 min(-1) and 3782.89 +/- 2686.72 L/kg and 0.524 +/- 0.157 min(-1) and 11713 +/- 7618.68 L/kg, respectively. The experimental results of the pharmacokinetic parameters of Meranzin hydrate and ferulic acid indicate that they were absorbed and distributed rapidly. CONCLUSIONS: The pharmacodynamics and pharmacokinetics of prokinetic Chaihu-Shugan-San and its compounds are useful for monitoring Chaihu-Shugan-San formulas in clinical practice and for understanding therapeutic mechanisms.
